US009410943B2

(12) **United States Patent**
Kadoch et al.

(10) **Patent No.: US 9,410,943 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **METHODS, COMPOSITIONS AND SCREENS FOR THERAPEUTICS FOR THE TREATMENT OF SYNOVIAL SARCOMA**

(71) Applicant: **The Board of Trustees of the Leland Stanford Junior University**, Palo Alto, CA (US)

(72) Inventors: **Cigall Kadoch**, Stanford, CA (US); **Gerald R. Crabtree**, Woodside, CA (US)

(73) Assignee: **The Board of Trustees of the Leland Stanford Junior University**, Stanford, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/210,087**

(22) Filed: **Mar. 13, 2014**

(65) **Prior Publication Data**

US 2014/0288162 A1 Sep. 25, 2014

Related U.S. Application Data

(60) Provisional application No. 61/783,895, filed on Mar. 14, 2013.

(51) **Int. Cl.**

A61K 31/661	(2006.01)
G01N 33/50	(2006.01)
G01N 33/574	(2006.01)
A61K 31/7105	(2006.01)

(52) **U.S. Cl.**

CPC ***G01N 33/5011*** (2013.01); ***A61K 31/661*** (2013.01); ***A61K 31/7105*** (2013.01); ***G01N 33/57407*** (2013.01)

(58) **Field of Classification Search**

CPC A61K 31/661

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

7,056,883	B2 *	6/2006	Ito et al.	514/19.3
2011/0061116	A1 *	3/2011	Haldar et al.	800/10

OTHER PUBLICATIONS

Eilber et al. 2007; Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Annals of Surgery. 246(1): 105113.*

Kadoch et al. 2013a; Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSx oncogenic fusion in synovial sarcoma. Cell 153: 71-85.*

Kadoch et al. 2013b; Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nature Geneticds. 45(6): 592-602.*

Conger. 2013. Protein complex may play role in preventing many forms of cancer, study shows. At: med.stanford.edu/news/all-news/2013/05/protein-complex-may-play-role-in-preventing-many-forms-of-cancer-study-shows.html.*

Takenaka et al. 2010; Downregulation of SS18-SSx1 expression in synovial sarcoma by small interfering RNA enhances the focal adhesion pathway and inhibits anchorage-independent growth in vitro and tumor growth in vivo. International Journal of Oncology. 36: 823-831.*

Thaete et al. 1999; Functional domains of the SYT and SYT-SSX synovial sarcoma translocation proteins and co-localization with the SNF protein BRM in the nucleus. Human Molecular Genetics. 8 (4): 585-591.*

Kasten et al. 2011; SnapShot: Chromatin remodeling: SWI/SNF. Cell 144: 310.*

Clark; et al., "Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma", Nature Genetics (Aug. 1994), 7(4):502-8.

De Leeuw; et al., "Identification of two alternative fusion genes, SYT-SSX1 and SYT-SSX2, in t(X;18)(p11.2;q11.2)-positive synovial sarcomas", Human Molecular Genetics (Jun. 1995), 4(6):1097-9.

Kadoch; et al., "Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy", Nature Genetics (Jun. 2013), 45(6):592-601.

Kadoch; et al., Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma, Cell (Mar. 2013), 153(1):71-85.

Roberts; et al., "Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5", Cancer Cell (Nov. 2002), 2(5):415-25.

Skytting; et al., "A novel fusion gene, SYT-SSX4, in synovial sarcoma", Journal of the National Cancer Institute (Jun. 1999), 91(11):974-5.

Svejstrup, "Synovial sarcoma mechanisms: a series of unfortunate events", Cell (Mar. 2013), 153(1):11-2.

Versteege; et al., "Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer", Nature (Jul. 1998), 394 (6689):203-6.

* cited by examiner

Primary Examiner — Karen Cochrane Carlson

(74) *Attorney, Agent, or Firm* — Glenn J. Foulds; Bret E. Field; Bozicevic, Field & Francis LLP

(57) **ABSTRACT**

Methods and compositions are provided for treating human synovial sarcoma (SS). Also provided are screens to identify therapeutics for the treatment of synovial sarcoma. These methods, compositions, and screens are based on the discovery that promoting the assembly of wild type BAF (also called mSWI/SNF) complexes in SS cells by increasing levels of wild type SS18 and/or decreasing levels of SS18-SSX fusion protein leads to the cessation of proliferation of malignant cells in synovial sarcoma.

17 Claims, 23 Drawing Sheets
(20 of 23 Drawing Sheet(s) Filed in Color)